Before the bell, see which firms are in the news.
Nvidia — Stock fell 2%, compounding losses from Nvidia’s 3.5% closing day loss on Thursday. The fall follows the AI chipmaker’s temporary victory over Microsoft on Tuesday as the most valued public firm.
Sarepta Therapeutics: Following the FDA’s approval of an extended use of Sarepta’s Elevidys gene therapy to treat patients with Duchenne muscular dystrophy, the biopharmaceutical company’s stock shot up 37%.
Nike: The sportswear manufacturer saw a 1% increase after Oppenheimer upgraded it from market perform to outperform. Additionally, the organisation reaffirmed Nike’s ranking as a top megacap selection, stating that the stock is expected to rise steadily as the business concentrates on developing its brand and creating new products.
Asana: Following the announcement of a $150 million share buyback plan, the software company’s shares surged by more than 3%. The business projects that it will carry out its stock repurchase programme until June 30, 2025.
Gilead Sciences: The pharmaceutical stock increased by almost 2.6%, extending its previous session’s 8.5% gain. Gilead reported on Thursday that a late-stage experiment using an HIV prophylaxis injection was successful.
LendingTree: Following Bloomberg’s revelation that hackers are now auctioning off stolen data from the website, shares of the online lending marketplace saw a little decline. A cyberattack against cloud computing company Snowflake targeted LendingTree.
Apple — Following Bernstein’s price boost, the iPhone maker’s stock slightly increased. the reason for the more optimistic forecast is that he believes Apple has the potential to lead the artificial intelligence boom rather than be a “laggard.”
Source (CNBC)
